Efficacy and safety of rituximab treatment in children with primary glomerulonephritis.
J Nephrol
; 25(6): 1060-6, 2012.
Article
en En
| MEDLINE
| ID: mdl-22322817
ABSTRACT
BACKGROUND:
The aim of our study was to analyze the efficacy and safety of rituximab, a chimeric monoclonal antibody against CD20 lymphocytes, as a nonstandard immunosuppressive therapy in children with different types of primary glomerulonephritis who were not eligible for routine treatment.METHODS:
The study group was composed of 16 children with proteinuric glomerulopathies, not responding to standard immunosuppressive therapy. The indications included steroid-resistant nephrotic syndrome (n=14) and steroid-dependent nephrotic syndrome (n=2). The dose of rituximab was established as 375 mg/m2 of body surface area, administered by intravenous infusion once weekly for 1 to 4 weeks, depending on the CD19 lymphocyte count. We evaluated proteinuria and plasma concentration of CD19 lymphocytes at intervals of 1, 3 and 6 months, after which patients received a single repeat dose.RESULTS:
Remission, defined as proteinuria less than 150 mg per 24 hours, was observed in 7 of the 16 children. There were no statistically significant differences in leukocyte counts between single and multiple rituximab doses. We also did not observe any clinical or biochemical side effects.CONCLUSIONS:
In conclusion, we postulate that alternative rituximab therapy should be taken into consideration in nephrotic patients not responding to standard therapy.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Anticuerpos Monoclonales de Origen Murino
/
Glomerulonefritis
/
Inmunosupresores
Límite:
Adolescent
/
Child
/
Female
/
Humans
/
Male
Idioma:
En
Año:
2012
Tipo del documento:
Article